Produced By Deanna Utroske, 2
This month, multinational bioprinting technologies company Cellink announced having reached a deal to acquire Cytena for €30.25 million. The Freiburg, Germany – based venture specialises in single-cell printing technology. And the deal will expand Cellink’s capabilities in both pharma and cosmetics.
Cellink got its start in 2016 and is headquartered in Boston, Massachusetts, (in the US) where a lot of biotech businesses are located. The company makes and commercializes bioprinting technologies for use in academic research and industry. Bioprinting is essentially 3-dimentional printing technology that incorporates live cells and is used to create tissue and other components.
👉 The Skinobs team will be delighted to welcome you booth 857, to talk with…
At Byome Labs, we help cosmetic, dermo-cosmetic and pharmaceutical brands decode the invisible world of…
Nevisense is a non-invasive tool for monitoring skin barrier function with several applications in cosmetic…